Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
News

News

This menu lists current news relating to corporate activities and resources or internet links relating to our industry.

The NEI Awards $2.03 Million Commercialization SBIR Grant to Aciont - 05/09/2013
Salt Lake City, UT – May 9, 2013. The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.03 million phase IIB grant to Aciont Inc. to fund the clinical development of a non-invasive, passive diffusion-based treatment for uveitis (referred to as DSP-Visulex-TM). The NEI special emphasis peer review panel that reviewed Aciont’s proposal stated, “Overall, this is a novel, exciting approach that has potential to make a broad impact in the clinical ophthalmology field and thus is recommended with a high level of enthusiasm.”
 
Aciont® to Present at ARVO 2013 Annual Meeting - 04/15/2013
Aciont Inc. announced today that Dr. Sarah A. Molokhia and Dr. Kongnara Papangkorn will present recent findings on two Visulex-TM technologies
 
Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference - 01/10/2012
Kongnara Papankorn and Sarah Molokhia will present on behalf of Aciont Inc at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012, in Las Vegas, NV
 
Aciont® CEO to Present at IN3 West Medical Device Conference - 02/08/2011
John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device Conference.
 
Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K - 11/04/2010
Aciont Inc. announced today that it has been awarded $488,958 to support two projects under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program.
 
University of Michigan Science Symposium Honoring Professor William I. Higuchi - 09/23/2010

 
The NIH Awards Aciont® a Small Business Catalyst Award Grant Accelerating Innovative Research - 07/07/2010
Aciont is awarded a phase I SBIR $214K grant for the project titled "Novel Method for the Ocular Iontophoretic Delivery of Avastin® and Lucentis®"
 
Aciont® To Present at ARVO 2010 Annual Meeting - 04/09/2010

 
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont® - 12/10/2009
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis.
 
Aciont ARVO 2009 Presentations Article - 05/04/2009

 
Tribute to William I. Higuchi in Journal of Pharmaceutical Sciences - 01/15/2008
Dr. Higuchi's contributions have significantly elevated the field of pharmaceutics. He has an impressive body of scientific work and a continuing legacy of his accomplishments.
 
Aciont's Research Discussed in Two Recent Ophthalmic Publications - 11/21/2008
Aciont's research is published in Investigative Ophthalmology & Visual Science journal and Journal of Ocular Pharmacology and Therapeutics.
 
NEI Awards Ocular Iontophoresis Research Grant to Aciont® Collaborators - 01/18/2007
Understanding of ocular pharmacokinetics and transport barriers of the eye would be a major step toward achieving a non-invasive drug delivery system to treat posterior segment of eye diseases.
 
Aciont® Featured in Retina Today Article - 03/01/2007
Dr. Karl G. Csaky's article features new and exciting technologies in transscleral drug delivery.
 
Aciont Announces SBIR Funding to Support the Development of its Back-of-the-Eye Therapy Technology - November 2004 - 11/09/2004

 
Aciont's Visulex Technology Highlighted in Leading Drug Delivey Trade Magazine - 04/15/2004
Advancing iontophoresis for effective noninvasive back-of-the-eye therapeutics.
 
Aciont® Featured in Digital IQ Article - 06/04/2003

 
Aciont® Inc Awarded NIH Grant - 04/25/2002
Awarded a Phase-I Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH) for $100,000 payment based on the competitive merit of Aciont's proposal and technology.